LONDON, Jan 24 (Reuters) - European drugs regulators gavetheir backing on Friday for marketing authorisations to begranted for Bayer's drug Adempas, designed to treatpulmonary hypertension, and for GlaxoSmithKline's diabetes medicine Eperzan.
The regulator also backed a new drug from Dainippon SumitomoPharma called Latuda, for the treatment ofschizophrenia, and Bemfola, a new biosimilar medicine for thetreatment of infertility.
But the European Medicine Agency (EMA) recommended rejectingan application from the Swiss drugmaker Novartis to market itsheart failure drug serelaxin.